CamGene Therapeutics develops RNA‑based medicines that target the molecular causes of sensorineural hearing loss. Using a lipid nanoparticle delivery platform, it transports mRNA, siRNA, antisense oligonucleotides and other RNA modalities to cochlear cells to promote hair‑cell regeneration or protection, aiming to provide a scalable, cost‑effective pharmacologic alternative to hearing devices.
Funding
Funding not disclosed
Founders
Product
Problem
Hearing loss affects a large and growing portion of the global population, yet current standard-of-care devices address symptoms without correcting the underlying cellular dysfunction. There are no approved medicines that target the molecular causes of sensorineural hearing loss, leaving many patients without disease-modifying options.
Solution
CamGene Therapeutics develops RNA‑based medicines that aim to treat the root causes of hearing loss by modulating protein expression in the cochlea. Using lipid nanoparticle (LNP) delivery, the platform can transport mRNA, siRNA, antisense oligonucleotides and other RNA modalities directly to key inner‑ear cells. The approach is designed to promote regeneration or protect hair cells and supporting structures, offering a pharmacologic alternative to devices. Manufacturing is built for cost‑effective scale, enabling the creation of accessible mass‑market treatments. Clinical development focuses on delivering precise, molecular‑level interventions that can be administered systemically or locally to patients with various forms of sensorineural hearing loss.
Target Audience
Primary customers are pharmaceutical developers and otology specialists seeking disease‑modifying treatments for sensorineural hearing loss, as well as patients who lack effective therapeutic options beyond hearing aids or implants.
Features
- Lipid nanoparticle delivery system optimized for safe, efficient transport of diverse RNA therapeutics to cochlear cells
- Capability to use multiple RNA modalities (mRNA, siRNA, antisense oligonucleotides) for gene activation, silencing, or editing
- Targeted modulation of protein pathways involved in hair cell regeneration and protection
- Scalable manufacturing process designed to keep production costs low for broad market access
- Preclinical platform integrating otology expertise and RNA technology to accelerate candidate selection and validation